Pursuing vulnerable plaque biomarkers and druggable targets
This article was originally published in Start Up
Cambridge, UK-based PlaqueTec Ltd. is developing a coronary artery blood sampling technology combined with biomarker analysis to map the biological processes associated with the development and rupture of vulnerable plaque. The ambitious young company plans to use this information to detect and monitor plaque biomarkers, and then use these patented data to help identify drug candidates for atherosclerosis.
You may also be interested in...
The EU Batteries Regulation is yet another legal instrument medical device manufacturers must address over the coming years alongside the core Medical Device and IVD Regulations.
Worryingly, however, British consumers are also increasingly turning to social media for health information, and rejecting it if it conflicts with what they believe, or if it is not based on personal experience.
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.